Navigation Links
Carnegie Mellon researchers create fluorescent biosensor to aid in drug development
Date:7/29/2010

Researchers at Carnegie Mellon University have developed a new fluorescent biosensor that could aid in the development of an important class of drugs that target a crucial class of proteins called G protein-coupled receptors (GPCRs).

"Drugs that target GPCRs make up approximately 30 percent of all pharmaceuticals currently on the market, including some of the most prescribed drugs," said Jonathan Jarvik, the Carnegie Mellon professor who led the effort to develop the GPCR biosensor. "This prevalence makes assays for the receptors a billion dollar industry."

GPCRs are popular drug targets because of the pivotal role they play in cells' chemical communication circuits that are responsible for regulating functions critical to health, including circuits involved in heart and lung function, mood, cognition and memory, digestion and the inflammatory response. Found in the cell membrane, GPCRs interact with molecules responsible for cellular communication such as neurotransmitters and hormones. When one of the receptors encounters such a molecule, it relays a signal across the cell membrane that, in turn, initiates a response. After the response is triggered, the receptor retreats from the membrane into the cell's interior.

To create the GPCR biosensor, the research team used a new technology called fluoromodules. Invented by Carnegie Mellon's Molecular and Biosensor Imaging Center (MBIC), fluoromodules are probes that allow scientists to monitor the activities of individual proteins found in living cells in real-time. The probes are made up of two components: a fluorogen-activating protein (FAP) and a non-fluorescent dye called a fluorogen. The FAP is attached to the protein that is being studied, and the fluorogen is engineered to bind to the FAP. When the two meet, they cast off a glow that can be detected using a variety of methods, alerting researchers to the protein's location and activity. The FAP's fluorescence can be turned on and off by adding or removing the fluorogen, a characteristic that makes the fluoromodules more useful than other fluorescent proteins.

In the current study, which is published in the July issue of the Journal of Biomolecular Screening, Jarvik and colleagues engineered a fluoromodule that would readily determine when GPCR retreats from the cell membrane. The researchers genetically expressed a FAP fused to the beta2 adrenergic receptor (β2AR), a well-studied GPCR that is present in brain, heart, lung and other tissues. When the researchers introduced its associated membrane-impermeant fluorogen, it bound to the FAP-tagged GPCR on the cell surface, emitting a bright fluorescent glow. When the receptor was activated and had retreated into the cell, the fluorescence dimmed.

The new biosensor is notable, Jarvik said, because it looks directly at the receptor and provides what is known as a homogeneous, or mix-and-read, assay that can be scaled to screen large numbers of molecules to identify new drug leads.

The researchers are hopeful that this technology can be generalized across other receptors and cell-surface proteins, and are currently researching its broader applications.


'/>"/>

Contact: Jocelyn Duffy
jhduffy@andrew.cmu.edu
412-268-9982
Carnegie Mellon University
Source:Eurekalert

Related biology news :

1. Carnegies Doug Koshland elected to National Academy of Sciences
2. Carnegies Chris Field elected to American Academy of Arts & Sciences
3. Carnegie Mellon researchers seek to control blood loss
4. Carnegie Mellons Sanna Gaspard named New Face of Engineering
5. Carnegie Mellon first to measure energy released from a virus during infection
6. Carnegie Mellons John Kitchin receives early career award
7. Carnegie Mellons Philip LeDuc discovers new protein function
8. Carnegie Mellon engineers develop machine that visually inspects and sorts strawberry plants
9. Carnegie Mellon researchers receive grant
10. Carnegie Mellon customizing electric cars for cost-effective urban commuting
11. Carnegie Mellon researchers to develop probes to study cellular GPS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
Breaking Biology Technology: